Lymphangioleiomyomatosis (LAM)
Page Content
Lymphangioleiomyomatosis
(LAM) is a cystic lung disease that may progressively destroy the lung
structure. Alterations in the lymphatic system and renal tumors are further
characteristics of the disease. LAM patients may suffer from a progressively
impaired lung function and dyspnea. Pneumothorax is a known complication,
typically precedes or leads to diagnosis of LAM and requires sometimes-surgical
intervention.
LAM is a rare lung disease (5 out of 1 mio.) and affects mainly woman in childbearing
age. Diagnosis is typically delayed many years and experts with experience in
treatment and follow-up are rare.
mTOR-Inhibitors
such as Sirolimus allow to stabilize or slow down decrease of lung function and
improve some measures of life in LAM.
We care for
more than 20 patients with LAM and work together with national and
international experts in the field. We are part of the tuberous sclerosis
network of Zurich.
Extensive
information can be found on the Webside of the LAM foundation
For further
information:
PD Dr. med.
Christian Clarenbach
Klinik für Pneumologie
UniversitätsSpital Zürich
Rämistrasse 100
8091 Zürich
christian.clarenbach@usz.ch
Last update: 11.07.2019 | Person responsible:
Professor Malcolm Kohler, MD